NCT00138541已完成3 期
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 440
- 试验地点
- 2
- 主要终点
- Change from baseline in HbA1c at 52 weeks
研究概览
简要总结
This is a 28-week extension to a study of the safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather long-term safety and efficacy data for vildagliptin in people with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only patients successfully completing study CLAF237A2301 are eligible
- •Written informed consent
- •Ability to comply with all study requirements
排除标准
- •Premature discontinuation from study CLAF237A2301
- •Other protocol-defined exclusion criteria may apply
结局指标
主要结局
Change from baseline in HbA1c at 52 weeks
Safety of vildagliptin during 52 weeks of treatment
次要结局
- Change in fasting plasma glucose between 24 weeks and 52 weeks
- Change from baseline in HOMA B at 52 weeks
- Change from baseline in HOMA IR at 52 weeks
- Change in HbA1c between 24 weeks and 52 weeks
- Change from baseline in fasting plasma glucose at 52 weeks
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138619Novartis478
已完成
3 期
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00138567Novartis530
已完成
3 期
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)Diabetes Mellitus, Type 2Renal InsufficiencyNCT00765830Novartis349
已完成
3 期
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00099905Novartis Pharmaceuticals639
已完成
3 期
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)Renal InsufficiencyDiabetes Mellitus, Type 2NCT00770081Novartis75